Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-FCM vs FCM in Relapsed Lymphoma
NCT00317096Phase 3Unknown
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Nov 1998
- Primary completion
- Jun 2001
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in follicular lymphoma (FL), mantle cell lymphoma (MCL), Lymphoplasmacytic Lymphoma (LPL), sponsored by Ludwig Maximilian University of Munich. Status: unknown.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)mantle cell lymphoma (MCL)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on NCT00317096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00317096.